As a further sign that all may not be well in Big Pharma, AstraZeneca is believed to be looking at options for its Sweden-based GI business. The favoured option is thought to be a venture capital backed spin off company.
The Times
Tuesday, 12 February 2008
AstraZeneca may spin off GI research
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment